Brought to you by 
ZAI Lab brings in over $100mm through Series B round
11 Jan 2016
Executive Summary
Chinese biotech Zai Lab Ltd. raised over $100mm through its Series B round. Advantech Capital led and was joined by OrbiMed and returning backers Qiming Ventures, Sequoia Capital China, and TF Capital. The funding will support ZAI's pipeline of candidates in development for cancer (including a NSCLC compound licensed from Hanmi late last year), asthma, COPD, IBD, and graft-versus-host disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ZAI Lab brings in over $100mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice